Methods for treating conditions associated with lectin-dependent complement activation
First Claim
1. A method of inhibiting lectin-dependent complement activation in a subject in need thereof, comprising administering to the subject an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
1 Assignment
0 Petitions
Accused Products
Abstract
In one aspect, the invention provides methods of inhibiting the effects of lectin-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation. In some embodiments, the MAp19 inhibitory agent inhibits cellular injury associated with lectin-mediated complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides MAp19 specific antibodies that do not bind to MASP-2 and methods of producing MAp19 specific antibodies. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MAp19 inhibitory agent and a pharmaceutically acceptable carrier.
-
Citations
56 Claims
- 1. A method of inhibiting lectin-dependent complement activation in a subject in need thereof, comprising administering to the subject an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
-
14. A method of inhibiting lectin-dependent complement activation in a subject in need thereof, comprising administering to the subject an amount of a MAp19 inhibitory agent effective to selectively inhibit lectin complement activation without substantially inhibiting C1q-dependent complement activation.
- 15. An anti-MAp19 antibody that does not bind to MASP-2.
- 18. A method of producing an anti-human MAp19 antibody that does not cross-react with human MASP-2 comprising generating a murine MAp19 deficient transgenic animal, integrating a human MASP-2 transgene into said murine MAp19 deficient animal, introducing a human MAp19 antigen into said animal, and selecting anti-human MAp19 antibodies that do not bind to human MASP-2.
-
21. A composition for inhibiting lectin-dependent complement activation comprising a therapeutically effective amount of a MAp19 inhibitory agent and a pharmaceutically acceptable carrier.
-
22. A method of manufacturing a medicament for use in inhibiting the effects of lectin-dependent complement activation in living subjects in need thereof, comprising combining a therapeutically effective amount of a MAp19 inhibitory agent in a pharmaceutical carrier.
-
23. A method for treating a patient deficient in MAp19 by administering to the patient a polypeptide comprising SEQ ID NO:
- 3, or a portion thereof.
- 24. A method of treating a subject suffering from a lectin-dependent complement mediated vascular condition comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 26. A method of treating a subject suffering from a lectin-dependent complement mediated condition associated with an ischemia-reperfusion injury comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
-
28. A method of treating and/or preventing atherosclerosis in a subject in need thereof, comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 29. A method of treating a subject suffering from a lectin-dependent complement mediated condition associated with an inflammatory gastrointestinal disorder comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 31. A method of treating a subject suffering from a lectin-dependent complement mediated pulmonary condition comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 33. A method of inhibiting lectin-dependent complement activation in a subject that has undergone, is undergoing, or will undergo an extracorporeal reperfusion procedure comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 35. A method of treating a subject suffering from a lectin-dependent complement mediated musculoskeletal condition comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 37. A method of treating a subject suffering from a lectin-dependent complement mediated renal condition comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 39. A method of treating a subject suffering from a lectin-dependent complement mediated skin condition comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 41. A method of inhibiting lectin-dependent complement activation in a subject that has undergone, is undergoing, or will undergo an organ or tissue transplant procedure comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 43. A method of treating a subject suffering from a lectin-dependent complement mediated condition associated with a nervous system disorder or injury comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 45. A method of treating a subject suffering from a lectin-dependent complement mediated condition associated with a blood disorder comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 47. A method of treating a subject suffering from a lectin-dependent complement mediated condition associated with a urogenital condition comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 49. A method of treating a subject suffering from a lectin-dependent complement mediated condition associated with nonobese diabetes (Type-1 diabetes or Insulin-dependent diabetes mellitus) and/or complications associated with Type-1 or Type-2 (adult onset) diabetes comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
-
51. A method of inhibiting lectin-dependent complement activation in a subject that has undergone, is undergoing, or will undergo chemotherapeutic treatment and/or radiation therapy comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
-
52. A method of treating a subject suffering from a malignancy comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 53. A method of treating a subject suffering from an endocrine disorder comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
- 55. A method of treating a subject suffering from a complement mediated ophthalmologic condition comprising administering an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation.
Specification